A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past ...

There were 11 hypersensitivity reactions, all in patients receiving nivolumab. Reducing the infusion time for nivolumab and pembrolizumab to 10 minutes is feasible and safe, according to researchers.

The US Food and Drug Administration (FDA) has approved a shorter infusion time for ocrelizumab (Ocrevus) for patients with relapsing or primary progressive multiple sclerosis (MS), the company has ...

Tepezza (teprotumumab-trbw) is usually given as an infusion into your vein once every 3 weeks. A full course of treatment is 8 infusions, which takes about 5 months to complete. Tepezza’s dose is ...

Infusion therapy is a lifeline for people living with autoimmune disorders and chronic conditions. It’s also frequently ...

I speak with infusion leaders every day—from major health systems to independent infusion practices—and the same challenge comes up time and again: speed and efficiency with the intake and prior ...